IP Library Granted Patent US 7,626,042
Granted Patent B2
US 7,626,042 · App. 10/515,622 · Granted Dec 1, 2009

O-substituted hydroxyaryl derivatives

Assignee: Institute of Medicinal Molecular Design, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,626,042
App. No.
10/515,622
Granted
Dec 1, 2009
Kind
B2
Abstract

A medicament having inhibitory activity against NF-κB activation which comprises as an active ingredient a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof: wherein X represents a connecting group whose number of atoms in a main chain is 2 to 5 (said connecting group may be substituted), “A” represents an acyl group which may be substituted, (provided that unsubstituted acetyl group and unsubstituted acryloyl group are excluded,) or a C 1 to C 6 alkyl group which may be substituted, or A may bind to connecting group X to form a cyclic structure which may be substituted, “E” represents an aryl group which may be substituted or a heteroaryl group which may be substituted, ring Z represents an arene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above, or a heteroarene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above.

Claims (98)

1. A compound represented by formula (I-1) or a salt thereof:

wherein

A 1 represents

a 5 to 6-membered non-aromatic heterocyclic ring-carbonyl group which comprises at least one nitrogen atom as ring-constituting atoms (ring forming atoms) of said heterocyclic ring and binds to the carbonyl group at the nitrogen atom, and said heterocyclic ring may be substituted with one or more substituents independently selected from

an alkyl group,

an alkyl-oxy-carbonyl group, and

a carboxy group

E 1 represents a mono- or di-substituted phenyl group, wherein the substituents of the mono- and di-substituted phenyl group are independently selected from

a halogen atom;

an alkyl group;

a halogenated alkyl group;

an alkoxy group;

an aryl group;

an aryl-oxy group which may be substituted with an alkoxy group; and

an alkyl-carbonyl group,

ring Z 1 represents a benzene ring wherein said benzene ring has one or more substituents independently selected from

a halogen atom;

an alkyl group;

a halogenated alkyl group;

an alkenyl group which may be substituted with an aryl group;

an aryl group; and

a 5-membered heteroaryl group,

in addition to the group represented by formula —O-A 1 wherein A 1 has the same meaning as that defined above and the group represented by formula —CONH-E 1 wherein E 1 has the same meaning as that defined above.

2. The compound according to claim 1 or a salt thereof, wherein E 1 is a di-substituted phenyl group wherein the substituents of the di-substituted phenyl group are independently selected from

a halogen atom;

an alkyl group;

a halogenated alkyl group;

an alkoxy group; and

a phenyl-oxy group which may be substituted with an alkoxy group.

3. The compound according to claim 1 or a salt thereof, wherein E 1 is a di-substituted phenyl group wherein one of the substituents of the di-substituted phenyl group is trifluoromethyl group, and the other substituent is independently selected from

a halogen atom;

an alkyl group;

a halogenated alkyl group;

an alkoxy group; and

a phenyl-oxy group which may be substituted with an alkoxy group.

4. The compound according to claim 1 or a salt thereof, wherein A 1 is a 5 to 6-membered non-aromatic heterocyclic ring-carbonyl group wherein said 5 to 6-membered non-aromatic heterocyclic ring is selected from 1-pyrrolidinyl group, piperidino group, morpholino group, and 1-piperazinyl group, and said heterocyclic ring may be substituted with one or more substituents independently selected from

an alkyl group,

an alkyl-oxy-carbonyl group, and

a carboxy group.

5. The compound according to claim 1 or a salt thereof, wherein

ring Z 1 is a benzene ring wherein said benzene ring has one or more substituents independently selected from

a halogen atom;

an alkyl group;

a halogenated alkyl group;

an alkenyl group which may be substituted with a phenyl group,

a phenyl group, and

a 3-thienyl group,

in addition to the group represented by formula —O-A 1 wherein A 1 has the same meaning as that defined above and the group represented by formula —CONH-E 1 wherein E 1 has the same meaning as that defined above.

6. The compound according to claim 1 or a salt thereof, wherein

A 1 is a (pyrrolidin-1-yl)carbonyl group, a(morpholin-4-yl)carbonyl group, a (4-methylpiperazin-1-yl)carbonyl group, a [4-(ethoxycarbonyl)piperidin-1-yl]carbonyl group or a (4-carboxypiperidin-1-yl)carbonyl group,

E 1 is a 3,5-bis(trifluoromethyl)phenyl group, a 3-methoxy-5-(trifluoromethyl)phenyl group, a 2-chloro-5-(trifluoromethyl)phenyl group, a 2,5-bis(trifluoromethyl)phenyl group, a 2-methoxy-5-(trifluoromethyl)phenyl group or a 2-(4-methoxyphenoxy)-5-(trifluoromethyl)phenyl group,

the following partial formula (Iz 1 -1) in the formula (I-1) containing ring Z 1

is represented by the following formula (Iz 1 -2),

wherein R z1 represents a halogen atom a tert-butyl group, a 2-phenylethen-1-yl group, a trifluoromethyl group, a phenyl group or a 3-thienyl group.

7. The compound according to claim 6 or a salt thereof, wherein

A 1 is a (morpholin-4-yl)carbonyl group,

E 1 is a 3,5-bis(trifluoromethyl)phenyl group or a 2,5-bis(trifluoromethyl)phenyl group, and R z1 is a halogen atom.

8. The compound according to claim 6 or a salt thereof, wherein

A 1 is a (morpholin-4-yl)carbonyl group,

E 1 is a 3,5-bis(trifluoromethyl)phenyl group, and

R z1 is a chlorine atom.

9. The compound according to claim 6 or a salt thereof, wherein

A 1 is a (morpholin-4-yl)carbonyl group,

E 1 is a 2,5-bis(trifluoromethyl)phenyl group, and

R z1 is a bromine atom.

10. The compound according to claim 1 or a salt thereof, wherein

E 1 is

a di-substituted phenyl group wherein the substituents of the di-substituted phenyl group are independently selected from

a halogen atom,

an alkyl group,

a halogenated alkyl group,

an alkoxy group, and

a phenyl-oxy group which may be substituted with an alkoxy group;

a 2-methoxy phenyl group; or

a biphenyl-4-yl group.

11. The compound according to claim 1 or a salt thereof, wherein

E 1 is a 3,5- or 2,5-di-substituted phenyl group wherein one of the substituents of the 3,5- or 2,5-di-substituted phenyl group is trifluoromethyl group, and the other substituent is independently selected from

a halogen atom;

an alkyl group;

a halogenated alkyl group;

an alkoxy group; and

a phenyl-oxy group which may be substituted with an alkoxy group.

12. The compound according to claim 1 or a salt thereof, wherein

E 1 is a 3,5-bis(trifluoromethyl)phenyl group, a 2-chloro-5-(trifluoromethyl)phenyl group, a 2,5-bis(trifluoromethyl)phenyl group, a 3-methoxy-5-(trifluoromethyl)phenyl group, a 2-methoxy-5-(trifluoromethyl)phenyl group or a 2-(4-methoxyphenoxy)-5-(trifluoromethyl)phenyl group.

13. The compound according to claim 1 or a salt thereof, wherein

A 1 is a (pyrrolidin-1-yl)carbonyl group, a (morpholin-4-yl)carbonyl group, a (4-methylpiperazin-1-yl)carbonyl group, a [4-(ethoxycarbonyl)piperidin-1-yl]carbonyl group or a (4-carboxypiperidin-1-yl)carbonyl group.

14. The compound according to claim 1 or a salt thereof, wherein

the following partial formula (Iz 1 -1) in the general formula containing ring Z 1

is represented by the following formula (Iz 1 -2),

wherein R 1 represents

a halogen atom,

an alkyl group,

a halogenated alkyl group,

an alkenyl group which may be substituted with a phenyl group,

a phenyl group, or

a 3-thienyl group.

15. The compound according to claim 14 or a salt thereof, wherein

R z1 is atom, a halogen atom, a tert-butyl group, a 2-phenylethen-1-yl group, a trifluoromethyl group, a phenyl group or a 3-thienyl group.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 24, 2005
From: MUTO, SUSUMU; ITAI, AKIKO
To: INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC.
Reel/Frame 016913/0777 →
Priority Claims (1)
JP 2002-165482 · Jun 6, 2002 · national
Continuity (1)
Related Publication 20060094718A1 · May 4, 2006